Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Innoviva is a commercial-stage biopharma with a strong portfolio of royalty healthcare assets, including two new launches for Zevtera in S. aureus bacteremia and potentially zoliflodacinin in uncomplicated gonorrhea. The company's growing IST business, with products such as Giapreza and Xacduro leading the way, has performed well and is expected to continue on a healthy growth trajectory. These, combined with the company's steady stream of royalties from GSK and strategic investments, make it an attractive investment opportunity.

Bears say

Innoviva is a healthcare company diversified across three core business segments with their primary source of revenue coming from GSK-partnered assets. However, with declines in forecasted revenue for key products such as Relvar/Breo/Ellipta and Anoro, as well as a recent launch of Nortiva Bio, which may take time to drive meaningful revenue, there are concerns about the company's financial performance and overall valuation. In addition, their strategic investment in Armata Pharmaceuticals may face challenges in gaining market acceptance and generating significant revenue.

Innoviva (INVA) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 4 analysts, Innoviva (INVA) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.